Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1395244 | PMC |
| http://dx.doi.org/10.1113/jphysiol.1937.sp003554 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prevalence of chronic kidney disease in Western Australia, 2010-2020.
BMJ Open
January 2025
Deakin Health Economics, Institute for Health Transformation, Deakin University, Melbourne, Victoria, Australia.
Objective: To assess the prevalence and trends of chronic kidney disease (CKD) in Western Australia (WA) from 2010 to 2020 using linked pathology data.
Design: A retrospective observational cohort study using linked de-identified data from WA pathology providers, hospital morbidity records and mortality records.
Setting: A Western Australian population-based study.
The relationship between insulin resistance and fibroblast growth factor 23 in patients with non-diabetic pre-dialysis chronic kidney disease: a cross-sectional study.
Sao Paulo Med J
January 2025
Associate Professor, Department of Nephrology, Ankara Bilkent City Hospital, Ankara, Turkey.
Background: Insulin resistance often occurs in patients with chronic kidney disease (CKD) owing to mineral and bone metabolism disorders. Fibroblast growth factor (FGF)-23 and soluble klotho (s-KL) play crucial roles in linking CKD with mineral and bone metabolism.
Objective: This study aimed to examine the relationship between insulin resistance and FGF-23 and s-KL in patients with non-diabetic pre-dialysis patients with CKD.
The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review.
PLoS One
January 2025
College of Medicine, King Faisal University, Alahsa, Saudi Arabia.
Acute kidney injury (AKI) is a frequent clinical complication lacking early diagnostic tests and effective treatments. Novel biomarkers have shown promise for enabling earlier detection, risk stratification, and guiding management of AKI. We conducted a systematic review to synthesize evidence on the efficacy of novel biomarkers for AKI detection and management.
View Article and Find Full Text PDFCitrate in autosomal dominant polycystic kidney disease: biomarker or therapeutic agent?
Curr Opin Nephrol Hypertens
March 2025
Nephrology Division, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Purpose Of Review: This review highlights the latest findings regarding hypocitraturia in autosomal dominant polycystic kidney disease (ADPKD), from both experimental and clinical studies, exploring the underlying pathophysiology and potential therapeutic approach.
Recent Findings: Experimental studies have shown that the lodging of microcrystals in the tubules can trigger cyst formation and growth in polycystic kidney disease (PKD). ADPKD patients are prone to developing hypocitraturia in early stages, which could predispose to calcium microcrystal formation.
Objectives: This clinical study assessed the three-year, long-term effects of esaxerenone, a non-steroidal aldosterone receptor blocker, on Japanese patients with type 2 diabetes, diabetic kidney disease, and hypertension who were receiving renin-angiotensin system inhibitors.
Materials And Methods: Data from a computerized diabetic care database were used to retrospectively compare esaxerenone users (Group A) with non-esaxerenone users (Group B). Propensity score weighting was applied to Group B.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!